"Global PARP Inhibitor Market Overview:
Global PARP Inhibitor Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global PARP Inhibitor Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of PARP Inhibitor involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the PARP Inhibitor Market:
The PARP Inhibitor Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for PARP Inhibitor Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study PARP Inhibitor Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, PARP Inhibitor market has been segmented into:
Niraparib
Olaparib
Rucaparib
Talazoparib
Veliparib
Others
By Application, PARP Inhibitor market has been segmented into:
Ovarian Cancer
Fallopian Tube Cancer
Breast Cancer
Prostate Cancer
Pancreatic Cancer
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The PARP Inhibitor market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the PARP Inhibitor market.
Top Key Players Covered in PARP Inhibitor market are:
AstraZeneca
GlaxoSmithKline
Merck Co. & Inc
GlaxoSmithKline plc
AbbVie Inc
Clovis Oncology
Medivation
Johnson & Johnson Services
Inc
Pfizer Inc.
Repare Therapeutics
Inc.
Genentech
Inc.
Artios Pharma
Repare Therapeutics Inc.
Sierra Oncology
Inc.
KaryopharmTherapeutics Inc.
Ono Pharmaceutical Co. Ltd
Jiangsu Hengrui Medicine Co. Ltd
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: PARP Inhibitor Market by Type
4.1 PARP Inhibitor Market Snapshot and Growth Engine
4.2 PARP Inhibitor Market Overview
4.3 Niraparib
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Niraparib: Geographic Segmentation Analysis
4.4 Olaparib
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Olaparib: Geographic Segmentation Analysis
4.5 Rucaparib
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Rucaparib: Geographic Segmentation Analysis
4.6 Talazoparib
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Talazoparib: Geographic Segmentation Analysis
4.7 Veliparib
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Veliparib: Geographic Segmentation Analysis
4.8 Others
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Others: Geographic Segmentation Analysis
Chapter 5: PARP Inhibitor Market by Application
5.1 PARP Inhibitor Market Snapshot and Growth Engine
5.2 PARP Inhibitor Market Overview
5.3 Ovarian Cancer
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Ovarian Cancer: Geographic Segmentation Analysis
5.4 Fallopian Tube Cancer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Fallopian Tube Cancer: Geographic Segmentation Analysis
5.5 Breast Cancer
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Breast Cancer: Geographic Segmentation Analysis
5.6 Prostate Cancer
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Prostate Cancer: Geographic Segmentation Analysis
5.7 Pancreatic Cancer
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Pancreatic Cancer: Geographic Segmentation Analysis
5.8 Others
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 PARP Inhibitor Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ASTRAZENECA
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 GLAXOSMITHKLINE
6.4 MERCK CO. & INC
6.5 GLAXOSMITHKLINE PLC
6.6 ABBVIE INC
6.7 CLOVIS ONCOLOGY
6.8 MEDIVATION
6.9 JOHNSON & JOHNSON SERVICES
6.10 INC
6.11 PFIZER INC.
6.12 REPARE THERAPEUTICS
6.13 INC.
6.14 GENENTECH
6.15 INC.
6.16 ARTIOS PHARMA
6.17 REPARE THERAPEUTICS INC.
6.18 SIERRA ONCOLOGY
6.19 INC.
6.20 KARYOPHARMTHERAPEUTICS INC.
6.21 ONO PHARMACEUTICAL CO.
6.22 LTD.
6.23 JIANGSU HENGRUI MEDICINE CO.
6.24 LTD.
Chapter 7: Global PARP Inhibitor Market By Region
7.1 Overview
7.2. North America PARP Inhibitor Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Niraparib
7.2.4.2 Olaparib
7.2.4.3 Rucaparib
7.2.4.4 Talazoparib
7.2.4.5 Veliparib
7.2.4.6 Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Ovarian Cancer
7.2.5.2 Fallopian Tube Cancer
7.2.5.3 Breast Cancer
7.2.5.4 Prostate Cancer
7.2.5.5 Pancreatic Cancer
7.2.5.6 Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe PARP Inhibitor Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Niraparib
7.3.4.2 Olaparib
7.3.4.3 Rucaparib
7.3.4.4 Talazoparib
7.3.4.5 Veliparib
7.3.4.6 Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Ovarian Cancer
7.3.5.2 Fallopian Tube Cancer
7.3.5.3 Breast Cancer
7.3.5.4 Prostate Cancer
7.3.5.5 Pancreatic Cancer
7.3.5.6 Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe PARP Inhibitor Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Niraparib
7.4.4.2 Olaparib
7.4.4.3 Rucaparib
7.4.4.4 Talazoparib
7.4.4.5 Veliparib
7.4.4.6 Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Ovarian Cancer
7.4.5.2 Fallopian Tube Cancer
7.4.5.3 Breast Cancer
7.4.5.4 Prostate Cancer
7.4.5.5 Pancreatic Cancer
7.4.5.6 Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific PARP Inhibitor Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Niraparib
7.5.4.2 Olaparib
7.5.4.3 Rucaparib
7.5.4.4 Talazoparib
7.5.4.5 Veliparib
7.5.4.6 Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Ovarian Cancer
7.5.5.2 Fallopian Tube Cancer
7.5.5.3 Breast Cancer
7.5.5.4 Prostate Cancer
7.5.5.5 Pancreatic Cancer
7.5.5.6 Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa PARP Inhibitor Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Niraparib
7.6.4.2 Olaparib
7.6.4.3 Rucaparib
7.6.4.4 Talazoparib
7.6.4.5 Veliparib
7.6.4.6 Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Ovarian Cancer
7.6.5.2 Fallopian Tube Cancer
7.6.5.3 Breast Cancer
7.6.5.4 Prostate Cancer
7.6.5.5 Pancreatic Cancer
7.6.5.6 Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America PARP Inhibitor Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Niraparib
7.7.4.2 Olaparib
7.7.4.3 Rucaparib
7.7.4.4 Talazoparib
7.7.4.5 Veliparib
7.7.4.6 Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Ovarian Cancer
7.7.5.2 Fallopian Tube Cancer
7.7.5.3 Breast Cancer
7.7.5.4 Prostate Cancer
7.7.5.5 Pancreatic Cancer
7.7.5.6 Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
PARP Inhibitor Scope:
|
Report Data
|
PARP Inhibitor Market
|
|
PARP Inhibitor Market Size in 2025
|
USD XX million
|
|
PARP Inhibitor CAGR 2025 - 2032
|
XX%
|
|
PARP Inhibitor Base Year
|
2024
|
|
PARP Inhibitor Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AstraZeneca, GlaxoSmithKline, Merck Co. & Inc, GlaxoSmithKline plc, AbbVie Inc, Clovis Oncology, Medivation, Johnson & Johnson Services, Inc, Pfizer Inc., Repare Therapeutics, Inc., Genentech, Inc., Artios Pharma, Repare Therapeutics Inc., Sierra Oncology, Inc., KaryopharmTherapeutics Inc., Ono Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd..
|
|
Key Segments
|
By Type
Niraparib
Olaparib
Rucaparib
Talazoparib
Veliparib
Others
By Applications
Ovarian Cancer
Fallopian Tube Cancer
Breast Cancer
Prostate Cancer
Pancreatic Cancer
Others
|
